Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer (inbunden)
Format
Inbunden (Hardback)
Språk
Engelska
Antal sidor
648
Utgivningsdatum
2010-06-08
Upplaga
1
Förlag
John Wiley & Sons Inc
Illustrationer
Illustrations
Dimensioner
241 x 165 x 38 mm
Vikt
1111 g
Antal komponenter
1
ISBN
9780470243725
Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer (inbunden)

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Inbunden Engelska, 2010-06-08
1549
Skickas inom 5-8 vardagar.
Fri frakt inom Sverige för privatpersoner.
Finns även som
Visa alla 2 format & utgåvor
Oncology Book of 2011, British Medical Association's Medical Book Awards Awarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.
Visa hela texten

Passar bra ihop

  1. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
  2. +
  3. Medical Imaging for Health Professionals

De som köpt den här boken har ofta också köpt Medical Imaging for Health Professionals av Raymond M Reilly (inbunden).

Köp båda 2 för 3148 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Fler böcker av Raymond M Reilly

  • Medical Imaging for Health Professionals

    Raymond M Reilly

    Describes the most common imaging technologies and their diagnostic applications so that pharmacists and other health professionals, as well as imaging researchers, can understand and interpret medical imaging science This book guides pharmacists ...

Recensioner i media

"The book is well written and the topics of individual chapters are wisely chosen in order to cover the most important aspects of targeted radionuclide therapy. This book gives rich insights into theoretical and practical aspects of targeted radionuclide therapy, particularly considering its position as a rapidly emerging, exciting, new therapy modality for cancer. It speaks in favor of this book that valuable information is available for people entering the field, as well as for experienced researchers who need profound information." ( ChemMedChem, November 2010)

Bloggat om Monoclonal Antibody and Peptide-Targeted ...

Övrig information

RAYMOND M. REILLY is a Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He has more than twenty years of experience in the field of radiolabeled antibody and peptide targeting of cancer. Dr. Reilly has written over 180 publications in the field, including more than 100 scientific papers on radiopharmaceuticals for cancer imaging and targeted radiotherapy.

Innehållsförteckning

Preface. Contributors. 1. Antibody Engineering: Optimizing the Delivery Vehicle (Diane E. Milenic). 1.1 Introduction. 1.2 Intact Murine Monoclonal Antibodies. 1.3 Recombinant Immunoglobulin Molecules. 1.4 Nanobodies. 1.5 Domain-Deleted Monoclonal Antibodies. 1.6 Hypervariable Domain Region Peptides. 1.7 Fv Fragments. 1.8 Minibodies. 1.9 Selective High Affinity Ligands. 1.10 Affibodies. 1.11 Other Strategies. 1.12 Concluding Remarks. References. 2. The Radiochemistry of Monoclonal Antibodies and Peptides (Raymond M. Reilly). 2.1 Introduction. 2.2 Tumor and Normal Tissue Uptake of Monoclonal Antibodies and Peptides. 2.3 Selection of a Radionuclide for Tumor Imaging. 2.4 Selection of a Radionuclide for Targeted Radiotherapy. 2.5 Labeling Antibodies and Peptides with Radiohalogens. 2.6 Labeling Antibodies and Peptides with Radiometals. 2.7 Characterization of Radiolabeled mAbs and Peptides. 2.8 Summary. Acknowledgments. References. 3. The Design of Radiolabeled Peptides for Targeting Malignancies (Leonard G. Luyt). 3.1 Introduction. 3.2 Peptide Targets. 3.3 Peptides as Cancer Targeting Agents. 3.4 Multimodality Agents. 3.5 Future Outlook. References. 4. Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors (Martijn van Essen, Dik J. Kwekkeboom, Wouter W. de Herder, Lisa Bodei, Boen L. R. Kam, Marion de Jong, Roelf Valkema, and Eric P. Krenning). 4.1 Introduction. 4.2 Radiotherapy with 111In-Octreotide. 4.3 Radiotherapy with 90Y-DOTATOC. 4.4 Targeted Radiotherapy Studies with 177Lu-Octreotate. 4.5 PRRT with Other Somatostatin Analogues. 4.6 Comparison of Different PRRT Studies. 4.7 Comparison with Chemotherapy. 4.8 Options for Improving PRRT and Future Directions. 4.9 Conclusions. References. 5. Targeted Radiotherapy of Central Nervous System Malignancies (Michael R. Zalutsky, David A. Reardon, and Darell D. Bigner). 5.1 Malignant Brain Tumors. 5.2 Rationale for Locoregional Therapy. 5.3 Targeted Radiotherapy of Brain Tumors. 5.4 Rationale for Tenascin-C as a Target for Radionuclide Therapy. 5.5 Perspective for the Future. Acknowledgments. References. 6. Radioimmunotherapy for B-Cell Non-Hodgkin Lymphoma (Thomas E. Witzig). 6.1 Introduction. 6.2 Radioimmunotherapy. 6.3 Antibodies Against CD22. 6.4 RIT Versus Immunotherapy. 6.5 RIT in Rituximab Refractory Patients. 6.6 RIT for Previously Untreated Patients. 6.7 RIT for Relapsed Large-Cell Lymphoma. 6.8 RIT for Transformed Lymphoma. 6.9 RIT for Mantle Cell Lymphoma. 6.10 Long-Term Results of RIT. 6.11 Risk of Myelodysplasia with RIT. 6.12 Feasibility of Treatment After RIT Failure. 6.13 Combinations of RIT and Chemotherapy. 6.14 High-Dose RIT with Stem Cell Support. 6.15 RIT for Central Nervous System Lymphoma. 6.16 Retreatment with RIT. 6.17 RIT in Children with Relapsed NHL. 6.18 RIT in Patients with Lung Involvement. 6.19 RIT in Patients with Skin Lymphoma. 6.20 RIT in Patients with >25% Marrow Involvement. 6.21 RIT in Older Patients. 6.22 RIT in Hodgkin s Disease. 6.23 Viral Infections After RIT. 6.24 Radiation Therapy After RIT. 6.25 Summary. 6.26 Future Directions. References. 7. Radioimmunotherapy of Acute Myeloid Leukemia (Todd L. Rosenblat and Joseph G. Jurcic). 7.1 Introduction. 7.2 Antigenic Targets. 7.3 Radionuclide Selection. 7.4 Radiolabeling. 7.5 Pharmacokinetics and Dosimetry. 7.6 RIT with b-Particle Emitters. 7.7 RIT with a-Particle Emitters. 7.8 Summary. References. 8. Pretargeted Radioimmunotherapy of Cancer (Robert M. Sharkey and David G. Goldenberg). 8.1 Introduction. 8.2 The Challenge of Improving Tumor/Nontumor Ratios. 8.3 Pretargeting: Uncoupling the Antibody Radionuclide Conjugate. 8.4 Clinical Studies of Pretargeting. 8.5 Prospects for Combination Therapies. 8.6 Future Innovations. 8.7 Conclusions. References. 9. Targeted Auger Electron Radiotherapy of Malignancies (Raymond M. Reilly and Amin Kassis)